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ABSTRACT
DAILY NOCTURNAL MELATONIN SUPPLEMENTATION IN
PERIMENOPAUSAL WOMEN: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED PILOT STUDY EXAMINING THE EFFECTS OF MELATONIN ON
BONE HEALTH AND QUALITY OF LIFE

By
Mary P. Kotlarczyk
December 2011

Dissertation supervised by Paula A. Witt-Enderby, Ph.D.
Objective: The purpose of this pilot study was to assess the effects of nightly
melatonin supplementation on primary endpoints of bone health and secondary endpoints
of quality of life in perimenopausal women.
Methods: A total of 18 perimenopausal women were randomized to receive
melatonin, 3 mg p.o., (n=13) or placebo (n=5) nightly for six months. Bone density was
measured by calcaneal ultrasound. Osteocalcin (OC), a bone formation marker, and
amino-terminal cross-linking telopeptide of type I collagen (NTX), a bone resorption
marker, were measured in serum samples taken bimonthly to assess changes in bone
turnover. Participants completed the Menopause-Specific Quality of Life-Intervention
(MENQOL) and Pittsburgh Sleep Quality Index (PSQI) questionnaires before treatment
and after six months. Subjects kept daily diaries recording menstrual cycling, well-being,
and sleep patterns.
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Results: No significant differences in bone density or bone turnover markers
were found with melatonin supplementation; however, there was a time-dependent trend
in the melatonin group towards an NTX:OC ratio of 1:1. A ratio of 1:1 could be an
indication of the ability of melatonin to balance bone resorption and bone formation to
maintain bone mass. Melatonin had no effect on vasomotor, psychosocial, or sexual
MENQOL domain scores after six months of nocturnal supplementation. However,
women taking melatonin had significant improvement in physical MENQOL domain
scores compared to placebo (-0.6 ± 0.8 and 0.1 ± 0.5, respectively). There were no
significant changes in PSQI score or average number of hours slept with melatonin
treatment. Analysis of menstrual cycling data showed women in the melatonin group had
significantly fewer periods (4.3 ± 0.6, n = 10 melatonin; 6.5 ± 0.3, n =4 placebo; mean ±
SEM) and longer days between periods (51.2 ± 11.4, n = 10 melatonin; 24.1 ± 0.9, n = 4
placebo) but showed no difference in duration of bleeding. Melatonin supplementation
was well-tolerated.
Conclusions: Melatonin may have the ability to regulate serum markers of bone
metabolism, indicating a potential role for melatonin in restoring imbalances in bone
remodeling and prevention of bone loss. The improvement in quality of life with
melatonin indicates supplementation may be beneficial for women experiencing physical
symptoms of menopause. Further investigation into how melatonin impacts bone health
and quality of life is warranted.
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INTRODUCTION
Perimenopause
A women‟s reproductive health changes throughout her lifetime. The typical
female reproductive cycle consists of three phases: the follicular phase, ovulation, and the
luteal phase. During the follicular phase, oocyte-containing follicles develop in the ovary
and secrete estradiol. Estradiol acts at the hypothalamus to trigger release of
gonadotropin-releasing hormone (GnRH), which activates receptors on the anterior
pituitary gland. Activation of these receptors induces secretion of follicle-stimulating
hormone (FSH) and luteinizing hormone (LH). FSH stimulates ovarian follicles to
develop further, with one dominant follicle becoming destined for ovulation. The
follicles continue to release estradiol. Low levels of estradiol inhibit secretion of LH
from the pituitary. When estradiol reaches a threshold level, however, it stimulates the
release of LH. The resulting surge in LH immediately precedes the release of the mature
egg from the follicle. During ovulation, the follicle ruptures and releases the egg from
the ovary. The remainder of the follicle develops into the corpus luteum, which secretes
estradiol and progesterone. During the luteal phase, the rising progesterone acts in the
uterus to thicken the endometrial lining for implantation. Estradiol and progesterone
exert negative feedback on the anterior pituitary to lower levels of FSH and LH.
Towards the end of the luteal phase, the corpus luteum atrophies and estradiol and
progesterone levels diminish. The loss of negative feedback on FSH secretion results in
rising levels of FSH. If no fertilization occurs, the endometrial lining is shed during
menstruation, and the cycle begins again.1 As women age, there is a decline in ovarian
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function due to depletion of follicle stores. An increasing amount of cycles are
anovulatory in which no egg is released. The changes in ovarian function result in
irregular patterns of endocrine hormone secretion. These variable changes continue until
there is complete cessation of the menstrual cycle (menopause).
The transition through menopause is unique to each woman; however, the
majority of women experience a change from regular menstrual cycling to irregular
menstrual periods and finally to cessation of menstruation.2 According to the Stages of
Reproductive Aging Workshop (STRAW), the main reproductive stages are classified
into three phases: reproductive, menopausal transition, and postmenopause.3 Stages are
described in terms of menstrual cycling and characteristic endocrine changes.

Figure 1: Stages of Reproductive Aging. The diagram above illustrates the main phases in
female reproductive aging according to the STRAW meeting including the reproductive stage
characterized by normal menstrual cycling, the menopausal transition (perimenopause) stage
identified by irregular cycling, and the postmenopause stage when there is cessation of the
menstrual cycle. Figure reprinted from Soules MR, Sherman S, Parrott E, et al. Stages of
Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med. Nov
2001;10(9):843-848, Copyright 2001, with permission from Mary Ann Liebert, Inc. publishers.
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As illustrated in Figure 1, the reproductive phase encompasses the time from
menarche to the onset of irregular menstrual cycles, which usually occurs when a women
is in her middle to late forties. The menopausal transition phase, including the
perimenopause stage, is characterized by variable menstrual cycling length and intervals
of amenorrhea (absence of a menstrual period). Perimenopause is defined as the stage
immediately before menopause and extending to the first year after menopause. The
postmenopause phase is the year after the final menstrual period to the end of life.
As noted, there is some overlap in the definition of stages, particularly concerning
the year after the final menstrual period. There is also ambiguity as to the definitive
starting and ending points to each stage. In this study, we chose to study melatonin
supplementation in perimenopausal women. There is no clinical test that indicates the
start or end of the perimenopausal state. An extensive review of the literature concluded
that perimenopause is characterized not by declining estrogen levels as traditionally
accepted; instead, perimenopausal women have periods of high estrogen compared to
premenopausal women.4 Estrogen and FSH levels fluctuate and are typically higher in
perimenopausal women.5 Due to the frequent fluctuations in reproductive hormones,
perimenopause is often accompanied by symptoms such as difficulty sleeping, vaginal
dryness, and vasomotor symptoms like hot flashes.6, 7 Signs of bone loss also begin to
occur during perimenopause, indicating the deterioration of bone seen in postmenopausal
osteoporosis may begin earlier than the onset of menopause.8-10

Osteoporosis
Osteoporosis is a bone disease that develops when there is an imbalance in bone
remodeling. Bone is constantly changing, undergoing a process of breakdown and
3

rebuilding. The remodeling process is under the control of two types of bone cells:
osteoclasts and osteoblasts. Osteoclasts are responsible for the resorption of old bone,
creating cavities, which are then replaced with new bone matrix by osteoblasts (Figure 2).

Figure 2: The bone remodeling process. Osteoclasts break down bone in the process of
resorption, creating cavities. Bone-forming osteoblasts fill in the areas of bone loss to complete
the remodeling process. Figure reprinted from Doheny MO, Sedlak CA, Estok P, Poirier V. DXA
valuable for bone mineral density testing. Nurse Pract. Nov 2003;28(11):44-49, Copyright 2003,
with permission from Wolters Kluwer Health, Inc.

An imbalance in the activity of osteoclasts and osteoblasts can lead to the development of
osteoporosis.11 It is believed that in osteoporosis, osteoclast activity outpaces osteoblast
activity, such that more bone is broken down than is being formed. This imbalance in
bone remodeling leads to an overall loss of bone mass and an increased risk of fracture.
In 2005, fractures resulted in $17 billion of direct medical costs. Costs are estimated to
exceed $20 billion by 2025; therefore, research into osteoporosis prevention is crucial.12
Role of reproductive hormones in osteoporosis
Women in particular are at greater risk for osteoporosis, accounting for 80% of
Americans diagnosed with osteoporosis.13 The increased incidence of osteoporosis in
women has largely been attributed to declining levels of estrogen during the menopausal
4

transition as decreases in circulating estrogen coincide with rapid bone loss and estrogen
replacement therapy is protective against bone loss. Emerging research has shown the
importance of other reproductive hormones, which may also play a role in the
development of postmenopausal osteoporosis, namely FSH and progesterone.
FSH levels are high during perimenopause, a time of significant bone loss in
women. Results from the Study of Women‟s Health Across the Nation (SWAN)
demonstrate a negative correlation between FSH levels and markers of bone metabolism
in premenopausal and early perimenopausal women.14 A study by Sun et al. showed
transgenic mice with reduced FSH levels but with functional reproductive systems had an
increase in trabecular bone mass and a decrease in tartrate-resistant acid phosphatase, a
serum marker of bone resoprtion.15 In vitro experiments showed functional FSH
receptors on human osteoclasts but not osteoblasts. The authors postulate that high levels
of FSH may increase bone resorption through activation of FSH receptors on osteoclasts.
15

The direct influence of FSH on bone metabolism is of some debate, especially given

the results of a recent study in which suppression of FSH in postmenopausal women did
not reduce markers of bone resorption.16 To remove any confounding influences of
estrogen on bone, women in both the control and treatment group were given an
aromatase inhibitor to decrease estrogen levels. Contrary to the study by Sun et al.15,
reducing FSH levels did not reduce levels on bone resorption markers or increase
markers of bone formation.16 Nevertheless, there is evidence to support a relationship
between FSH and bone metabolism either through direct activation of FSH receptors on
osteoclasts to stimulate bone resorption15 or via the modulatory effects of FSH on
hormones such as estrogen and progesterone.16
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A recent review by Seifert-Klaus and Prior details the evidence supporting a role
for progesterone in bone health.10 In fact, several in vitro studies show treatment with
progesterone can increase proliferation of human bone cells17, with proliferative effects
being enhanced with co-administered of estradiol.18, 19 The fluctuation in estrogen, FSH,
and progesterone levels occurring during perimenopause may contribute to the
deterioration of bone mass. Research demonstrating the possible roles of FSH and
progesterone in bone health indicate the need to examine not only estrogen but other
reproductive hormones when considering the pathology of postmenopausal osteoporosis.
Current Osteoporosis Treatments
To prevent the bone loss associated with menopause, it is recommended that
women have adequate daily intake of calcium and vitamin D. Even with calcium and
vitamin D supplementation, women are often prescribed medication to curb bone loss
associated with menopause. Most prescription therapies are targeted at inhibiting bone
resorption. These include agents such as calcitonin, bisphosphonates, selective estrogen
receptor modulators (SERMs), and more recently the receptor activator of NF-κB ligand
(RANKL) inhibitor denosumab. The parathyroid hormone (PTH) analog teriparatide is
the only FDA approved osteoporosis therapy that increases formation of new bone.
Calcitonin is an endogenous hormone that acts directly on receptors on osteoclasts
to decrease bone resorption. Calcitonin is approved for the treatment of postmenopausal
osteoporosis 5 years after menopause; however, the development of newer drugs has led
to a decline in calcitonin usage.20 Bisphosphonates are the most widely prescribed
therapy for prevention and treatment of postmenopausal osteoporosis.21 Bisphosphonates
are attracted to areas of high bone remodeling based on their ability to associate tightly
6

with hydroxyapatite, a main mineral component of bone. During bone remodeling,
osteoclasts take up bisphosphonate molecules on the bone surface. Bisphosphonates
induce apoptosis of osteoclasts to reduce bone resorption.22 While effective at preventing
bone loss and reducing fracture risk, bisphosphonate usage is not without side effects.
Women taking bisphosphonates have increased incidence of osteonecrosis of the jaw.23
Oversuppression of bone remodeling may also result in an increase in microdamage to
bone architecture.24 Concern has risen over a possible increase in atypical femur fracture
with long-term bisphosphonate therapy, although there is conflicting data regarding the
exact role of bisphosphonates in the occurrence of these fractures.25 Although not a
clinically established guideline, many have suggested bisphosphonate usage be limited to
a fixed length of time or that patients be given a “drug holiday” to reduce the risk of
untoward effects.
Estrogen replacement therapy can protect against the bone loss associated with
menopause; however, there are health concerns with long-term hormone replacement
therapy including increased risk of breast cancer and adverse cardiovascular events.26
The selective estrogen receptor modulator (SERM) raloxifene has been developed and
approved in the United States for both the prevention and treatment of postmenopausal
osteoporosis. SERMs possess both agonist and antagonist activity with responses being
tissue-specific. Raloxifene binds to the estrogen receptor to modulate estrogen-regulated
gene transcription. Depending on the tissue of action and the comodulators present,
raloxifene can act as an estrogen receptor agonist or antagonist. Raloxifene acts as an
estrogen receptor agonist in the bone, resulting in inhibition of osteoclast activity and
reduction of bone resorption.27 While SERMs maintain the beneficial effects of estrogen
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on bone, unwanted side effects with therapy include hot flashes, vaginal dryness, and
increased risk of venous thromboembolism.28 Side effects such as these can affect
patient compliance and may limit the duration of treatment.
Denosumab is a new therapy approved in 2010 for the prevention and treatment
of postmenopausal osteoporosis. Like bisphosphonates, denosumab decreases bone
resorption but does not do so through the same mechanism of inducing osteoclast
apoptosis. Denosumab is a monoclonal antibody, which binds to RANKL, an osteoclast
activator, thereby reducing osteoclast activity and bone resorption. Twice yearly
injections of denosumab for three years significantly reduced the risk of fracture in
osteoporotic women.29 As this is a new therapy, effects of long-term usage are not yet
known.
The parathyroid hormone (PTH) analog teriparatide is effective at increasing bone
mass by stimulating osteoblasts to form new bone. Teriparatide is a peptide composed of
PTH amino acids 1-34. Parathyroid hormone, like calcitonin, is an endogenous hormone,
which works to maintain calcium homeostasis. The action of PTH on bone depends on
the dose and length of exposure. Elevated PTH levels over extended periods of time lead
to activation of osteoclasts and an overall increase in bone resorption. However,
intermittent spikes in PTH levels, such as with once or twice daily injections of
teriparatide, stimulate PTH receptors on osteoblasts to increase activity of osteoblasts and
increase bone mass.30 This anabolic therapy is successful in increasing bone density,
improving the microarchitecture of the bone, and reducing risk of vertebral and
nonvertebral fractures.31 While PTH therapy is effective, patient compliance can be
affected by the need for subcutaneous injection. PTH therapy is limited to two-year
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duration, at which time antiresorptive therapy is often necessary to maintain bone mass
developed while on PTH.
Bone Turnover Markers
Bone turnover markers (BTMs) are biochemical indicators of bone remodeling
that are typically measured in blood or urine samples. Changes in bone turnover markers
occur more rapidly than alterations in bone mineral density (BMD) as measured by dualenergy x-ray absorptiometry (DXA). For this reason, biochemical markers of bone
turnover are gaining favor in clinical research, particularly for monitoring patient
response to osteoporosis therapies. Markers of bone formation, indicative of osteoblast
activity, include: osteocalcin (OC), bone-specific alkaline phosphatase (BAP),
procollagen type I N propeptide (PINP), and procollagen type I C propeptide (PICP).
With the exception of BAP, all of these markers are products synthesized by osteoblasts.
Bone-specific alkaline phosphatase is a membrane-bound enzyme on the osteoblast cell
surface. Bone resorption markers reflective of osteoclast activity include: amino-terminal
cross-linking telopeptide of type I collagen (NTX), carboxy-terminal cross-linking
telopeptide of type I collagen (CTX), deoxypyridinoline (DPD), pyridinoline (PYD), and
tartrate-resistant acid phosphatase (TRAP). NTX, CTX, DPD, and PYD are products of
type I collagen degradation which are released during bone resorption by osteoclasts.
TRAP is an enzyme of osteoclast origin.
Markers of bone turnover can be useful in monitoring responses to therapy. Bone
turnover markers typically show a decrease within 3-6 months of starting antiresorptive
therapy with bisphosphonates.32 Anabolic therapy with teriparatide also induces rapid
changes in bone turnover markers.33 The pattern and timing of how bone markers change
9

with treatment depend on the main mechanism of drug action. For example,
bisphosphonates strongly inhibit osteoclast activity. Bone resorption markers decline
early in the treatment period (around three months) while bone formation markers do not
decrease until approximately four weeks later when there is suppression of overall bone
turnover.34 On the other hand, therapy with the anabolic agent teriparatide significantly
increases bone formation markers within three months, reflecting the enhancement of
osteoblast activity. Bone resorption markers do not rise significantly above baseline until
approximately six months after beginning teriparatide treatment.34 Nevertheless, bone
markers allow for the assessment of treatment effects within a short period of time and
reflect the rapid cellular effects of therapy on bone metabolism. Monitoring fluctuations
in bone turnover markers can provide more rapid indications of patient compliance with
medication and the level of response to therapy. In this study, we utilize OC and NTX to
monitor changes in bone turnover markers after treatment with melatonin. These markers
were chosen because they have been utilized in previous studies of bone turnover
markers of perimenopausal women8, 9, 14, 35 and are known to be responsive to treatment
in postmenopausal women.36, 37 In addition, these markers can withstand storage before
detection which was required due to our rolling enrollment period. Other markers, such
as BAP, require more immediate measurement making assessment less conducive for our
study.

Melatonin
The current study examined melatonin supplementation in perimenopausal
women. Melatonin is an endogenous hormone produced in the pineal gland. Melatonin
levels are on a circadian cycle with higher levels found during periods of darkness.
10

Melatonin is synthesized from serotonin in the pineal gland. Serotonin is acetylated by
arylalkylamine N-acetyltransferase (AANAT) to yield N-acetylserotonin. HydroxyindolO-methyltransferase acts on N-actylserotonin to yield melatonin. Synthesis of melatonin
is under regulation of multisynaptic pathway originating in the suprachiasmatic nucleus
(SCN) of the hypothalamus and projecting into the pineal gland. Sympathetic signaling
through norepinephrine activates α1 and β1-adrenergic receptors on pinealocytes.
Activation of these receptors results in phosphorylation of transcription factors that
regulate production of AANAT, the rate-limiting enzyme in the melatonin synthetic
pathway. AANAT levels are highest during the dark, driving production of more
melatonin during this period.38 Light acts to depolarize retinal ganglion cells that
innervate the SCN, blocking sympathetic output to the pineal gland, thereby decreasing
synthesis of melatonin.39 Melatonin levels typically begin to rise at dusk and peak
around 02:00 hours.40 Light exposure at night inhibits the nocturnal increase in plasma
melatonin and can affect the circadian cycle of melatonin release.41 A study comparing
salivary melatonin secretion in subjects aged 18-45 found a decrease of 0.36 hours in the
duration of melatonin secretion for every 10 years of age.42 Peak levels of melatonin are
lower in middle-age and older subjects, with levels being as low as one-eighth that of
young adult levels.43, 44
Melatonin can exert effects through two known mammalian melatonin receptors:
MT1 and MT2. Both receptors are G-protein coupled receptors and signal largely through
Gi proteins to decrease cyclic adenosine monophosphate (cAMP) levels. However,
signaling pathways initiated by melatonin receptor activation vary depending on the
tissue of interest. (reviewed by Dubocovich, et al.45) MT1 and MT2 can also act via Gq
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proteins to increase intracellular calcium. MT2 has also been shown to decrease cyclic
cyclic guanosine monophosphate (cGMP). Internalization of MT2 receptors on human
adult mesenchymal stem cells (hAMSCs) may play a role in the differentiation process.
It has been proposed that desensitized MT2 receptors in hAMSCs can bind to β-arrestin
proteins creating a scaffold which can interact with proteins in the mitogen-activated
protein kinase (MAPK) pathway including mitogenic extracellular kinase 1/2 (MEK 1/2)
and extracellular signal-regulated kinase 1/2 (ERK 1/2) to induce differentiation.46 Aside
from interaction with its receptors, melatonin can exert various effects through its potent
antioxidant and free radical scavenging capabilities.47-49
Melatonin Effects on Bone
The relationship between melatonin and bone is well-documented.50-52 Melatonin
and enzymes essential for melatonin synthesis have been found in both mouse and human
bone marrow cells.53, 54 Melatonin levels in bone marrow can be orders of magnitude
higher than those in peripheral blood.53 Removal of the pineal gland (pinealectomy) in
rats significantly reduces both serum and bone marrow concentrations of melatonin
compared to control animals. Exogenous nightly administration of melatonin in drinking
water resulted in a significant increase in bone marrow melatonin compared to control
animals, suggesting exogenous melatonin is sequestered in bone marrow.53 Both the MT1
and MT2 melatonin receptors have been found on human osteoblasts.55-57 Melatonin
receptor expression on osteoclasts is unknown. The presence of melatonin biosynthetic
enzymes and melatonin receptors in the bone implies a direct role for melatonin in the
bone environment. Melatonin is thought to act on both osteoblasts and osteoclasts to
affect changes in bone tissue. In vitro, melatonin stimulates proliferation of extracted
12

human bone cells58 and enhances differentiation of rodent preosteoblast cells into
osteoblasts.59 Differentiation of hAMSCs into osteoblasts is also enhanced with
melatonin through MT2 receptor signaling.46, 60 Chronic treatment of hAMSCs with
melatonin in vitro significantly enhances expression of alkaline phosphatase, an
enzymatic marker of stem cell differentiation into an osteoblast, through action of the
MT2 receptor. The greatest increase in alkaline phosphatase was found to be when
melatonin receptors were desensitized as measured by a loss in radiolabeled melatonin
binding and a reduced ability of melatonin to inhibit forskolin-induced cAMP
accumulation.46 Melatonin acting through sensitized receptors also induced mRNA
expression of osteogenic genes; gene-induction was blocked by treatment with an MT2
selective antagonist.60 These studies demonstrate the capability of melatonin to enhance
differentiation of mesenchymal stem cells into osteoblasts and induce transcription of
osteogenic genes through the MT2 receptor.
In addition to promoting bone formation through actions on osteoblasts,
melatonin may also regulate osteoclast activity to reduce bone resorption. Bone
remodeling is a tightly coupled process. As illustrated in Figure 3, osteoblasts regulate
the activity of osteoclasts and bone resorption through the release of RANKL and
osteoprotegerin (OPG). RANKL is produced by osteoblasts and binds to RANK
receptors on osteoclast precursor cells to stimulate differentiation into mature osteoclasts.
The increase in mature osteoclast number leads to an increase in bone resorption. In
order to regulate bone loss associated with osteoclast activity, osteoblasts also release a
protein called osteoprotegerin which acts as a decoy. OPG binds to RANKL, preventing
RANKL from binding to RANK receptors and diminishing maturation of osteoclasts.61, 62
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Figure 3: Control of osteoclast activation by osteoblasts. Osteoblasts stimulate osteoclast
differentiation through release of RANKL. Increase in osteoclast activity leads to an increase in
bone resorption. Osteoblasts also regulate OPG release to bind RANKL and prevent RANKL
binding to RANK receptors. Figure reprinted from Coetzee M, Kruger MC. Osteoprotegerinreceptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis
treatment? South Med J. May 2004;97(5):506-511, Copyright 2004, with permission from
Wolters Kluwer Health, Inc.

In vitro treatment of mouse preosteoblast cells with melatonin increases the protein
osteoprotegerin and decreases RANKL mRNA transcript.63 By increasing release of
OPG from osteoblasts, melatonin may indirectly inhibit osteoclast activation and reduce
bone resorption. Melatonin, a potent free radical scavenger, may also inhibit bone
resorption by neutralizing the free radicals formed by osteoclasts to initiate bone
catabolism.52
Several in vivo studies demonstrate the association between melatonin deficiency
and bone disease. Pinealectomy in chickens induces formation of scoliotic curvature in
the vertebral column.64, 65 Treatment of pinealectomized chickens with melatonin
reduced the number of animals that developed scoliosis.66 Bipedal ambulation of
C57BL/6J mice results in the development of scoliosis. These mice inherently have
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almost no circulating melatonin; however, daily injections of melatonin to restore
circulating levels prevented scoliosis development in this model.67 Interestingly,
pinealectomy did not produce scoliosis in non human primates68; however, these animals
have the ability to support weight on all four limbs which may reduced stress on the
vertebral column. Little human data exists on the effects of melatonin on bone health;
although, melatonin is thought to play a possible role in the development of adolescent
idiopathic scoliosis (AIS). While circulating melatonin levels were not found to be
different in AIS patients69, researchers have found altered melatonin signaling in
osteoblasts from AIS patients compared to cells from healthy individuals.56, 70, 71
Melatonin had a reduced ability to inhibit forskolin-stimulated increases in cAMP in
osteoblast cells isolated from AIS patients.70 A subgroup of AIS patients showed an
increased coupling of MT2 receptors to Gs proteins as opposed to Gi as found in non-AIS
patients.56 The exact role of melatonin in AIS remains to be discovered, although MT2mediated melatonin signaling in the osteoblasts appears to be a factor in the etiology of
the disease.72
Changes in melatonin rhythms either through altered length of exposure to light73
or pinealectomy74 disrupts markers of bone turnover in rats, underscoring the connection
between melatonin and bone metabolism. Melatonin may work to increase bone
formation either directly through action on osteoblast differentiation or indirectly through
release of OPG to inhibit osteoclast activation and reduce bone resorption. Koyama et al.
found that melatonin, at pharmacological doses, increased bone mineral density by 36%
in young mice. Bone mass was also enhanced with melatonin as measured by increases in
trabecular bone thickness by 19%, and bone volume per tissue volume by 49%.
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Melatonin reduced parameters related to bone resorption including osteoclast surface
(74% decrease) and osteoclast number (76% decrease), but treatment had little effect on
bone formation measures (bone formation rate, mineral apposition rate, osteoid volume),
indicating action primarily through inhibition of resorption.63 Melatonin has also been
shown to enhance the amount of newly formed bone as measured by fluorescent labeling
in mice injected nightly with melatonin over 21 days.55 Studies in ovariectomized rats, a
model of postmenopausal osteoporosis, demonstrate the bone protective effects of
melatonin when adequate amounts of estradiol are given concurrently.75, 76 For example,
ovariectomized rats treated with melatonin nightly in drinking water had an increase in
bone area of the spine and increased bone mineral content of the tibia and skeleton. The
highest increases were seen in rats treated with a combination of nightly melatonin and 5
day/week injections of estradiol.76 There are currently no published human studies
examining melatonin for the prevention and/or treatment of osteoporosis; however, a
recent study of nurses with 20 or more years of night-shift work indicated a 37% increase
in hip and wrist fractures compared to those who never worked at night.77 This
information coupled with the knowledge that melatonin rhythms are shifted78 and
melatonin levels are altered in night-shift workers79 suggests a relationship between
altered melatonin levels and increased risk of fractures. Investigation into the bone
protective effects of melatonin in humans and its possible use in osteoporosis is
warranted.
Melatonin and Quality of Life
Aside from potential bone protective effects, melatonin may also improve quality
of life through improvements in sleep. Administration of 0.3 or 1.0 mg of melatonin to
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health volunteers decreased sleep onset latency and latency to stage 2 sleep as measured
by polysomnography; subjects reported no hangover effects the day after treatment.80
Indeed, a meta-analysis of sleep studies found that exogenous melatonin administration
decreases time to onset of sleep, increases sleep efficiency (percentage of time asleep out
of total time spent in bed), and increases the duration of sleep.81 Melatonin alleviates
insomnia and improves sleep quality in middle-aged to elderly patients without harmful
side effects.82 Treatment of perimenopausal women with 3 mg oral melatonin nightly for
6 months resulted in significantly improved mood with treatment compared to placebo
based on a survey developed by the study investigators. Many women in the melatonin
group reported improvements in sleep duration and quality, although results were not
statistically significant.83 Disturbances in sleep are a common symptom reported by
women during the menopausal transition.6 As this population is also at higher risk for
developing osteoporosis, a supplement such as melatonin may be beneficial at preventing
further bone loss while also alleviating sleep disturbances and improving quality of life.
Melatonin and Reproduction
Melatonin may enhance quality of life in perimenopausal women through
modulation of reproductive hormones. Melatonin has been established as a regulator of
reproduction in seasonally breeding animals; however, the role of melatonin in human
reproduction is not fully elucidated.84, 85 The exact mechanisms and role for melatonin in
reproduction may not be known; however, there is evidence melatonin moderates the
reproductive cycle at both a neuronal level and at the level of the reproductive organs.
Women with hypothalamic amenorrhea, a disease characterized by low GnRH levels,
were found to have higher peak melatonin concentrations and an extended duration of
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nighttime melatonin release,86, 87 implicating melatonin in the regulation of GnRH.
Indeed, melatonin induces cyclic decreases in steady-state levels of GnRH mRNA levels
in GT1-7 neuronal cells, a murine cell line capable of secreting GnRH. The effects of
melatonin were blocked by coadministration with the nonselective melatonin receptor
antagonist luzindole.88 In addition to regulating mRNA, melatonin suppress GnRH
secretion in GT1-7 cells.89 The actions of melatonin on GnRH appear to be mediated
through activation of melatonin receptors and the MAPK pathway.88, 89
In addition to effects on GnRH, melatonin has also been implicated in modulate
of reproductive hormones at the organ level. Melatonin, at concentrations higher than in
serum, has been found in the ovary, specifically preovulatory follicular fluid.90, 91
Melatonin in the follicular fluid has been hypothesized to play a role in reducing
oxidative damage and enhancing maturation of mature oocytes for ovulation.92 Melatonin
may also regulate ovarian function through receptor-meditated pathways as melatonin
receptor mRNA93, 94 and binding sites95 have also been discovered in ovarian granulosa
cells. Melatonin receptor mRNA and binding sites have also been identified in human
myometrium (uterine smooth muscle) biopsies.96 In vitro, melatonin sensitizes uterine
smooth muscle cells to procontractile signals, suggesting melatonin may play an
important role in preparing the uterus for labor.97, 98
Additional evidence of a role for melatonin in reproductive function includes the
correlations between melatonin and reproductive hormones. In vitro studies demonstrate
the ability of melatonin to enhance secretion of progesterone from human granulosa
cells94, 99 and corpus luteum.100 Conversely, melatonin has an inverse relationship with
estrogen such that when estrogen levels are high melatonin levels are low.101-104 A
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negative correlation between melatonin and FSH levels was found in perimenopausal
women, showing a decrease in melatonin as women transition through menopause.105
Aside from relationships between melatonin and other hormone levels, melatonin may
interfere with the ability of estradiol to mediate responses through the estrogen
receptor.106, 107 The complexities of how melatonin mediates responses in the
reproductive system are not well-understood, but the evidence supports a direct role for
melatonin in the human reproductive system.
Melatonin Supplementation
Melatonin is widely available as an over-the-counter oral supplement to relieve jet
lag and promote restful sleep. Pharmacokinetic studies of oral melatonin administration
show a plasma half-tlife (t1/2) of approximately 40-60 minutes with an estimated oral
bioavailability of 15-20%.108, 109 Oral melatonin undergoes extensive first past
metabolism in the liver, with much being excreted in the urine as 6-hydroxymelatonin
sulfate. Distribution of exogenous melatonin into body tissues has yet to be determined.
Timing of oral administration is important based on the intended effects of treatment.
Burgess et al. found that administration of 3 mg oral melatonin in the early morning
resulted in a phase delay while administration in the afternoon caused a phase advance;
administration of melatonin around bedtime had the least phase shifting effects.110
Different doses of melatonin may need to be timed differently to reduce the likelihood of
phase shifting one‟s circadian rhythm.110 In this study, we utilized a 3 mg dose of
melatonin. The effects of melatonin supplementation on bone have not been
investigated; therefore, there was no previous data to indicate the dose needed to alter
bone physiology. For this study, a dose was chosen that was known to produce a
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physiological effect. Melatonin was given at bedtime in order to minimize disruptions in
circadian rhythm.

Research Objective
Melatonin supplementation has the potential to prevent the bone loss associated
with perimenopause as well as relieve symptoms such as sleep disturbances that can
negatively impact quality of life. The purpose of this pilot study was to investigate the
effects of daily nocturnal melatonin supplementation in perimenopausal women over the
course of six months. Bone density and bone turnover markers were measured to
determine how melatonin effects bone health. Quality of life was also assessed through
validated questionnaires and daily participant diaries. This study was approved by the
Duquesne University Institutional Review Board.
Hypothesis
Daily nocturnal melatonin supplementation in perimenopausal women will
prevent decreases in bone density, regulate serum markers of bone metabolism, and
improve quality of life through regulation of sleep and improvement of menopausal
symptoms.
Specific Aims
1. Assess the feasibility of recruiting perimenopausal women willing to participate
in a blinded, randomized clinical study of melatonin versus placebo
2. Assess the effects of melatonin versus placebo on markers of bone health and
subject-reported outcomes of quality of life in perimenopausal women
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METHODS
Recruitment and Enrollment
Several recruitment strategies were utilized including advertisements in
neighborhood and city newspapers, posting of flyers, on-campus advertising via
Duquesne University‟s DU Daily website, and news features in the Duquesne University
Times and DU Alumni magazine. Interested women were instructed to call the study
phone number at which time a phone interview was scheduled. During the initial phone
screening, the expectations of the study were detailed, and the potential participant was
asked questions to determine eligibility. Inclusion criteria consisted of a woman being
age 45 or older, experiencing an irregular menstrual cycle, and having had at least one
menstrual period in the past six months. These criteria were used to define the potential
participant as perimenopausal. If all inclusion criteria were satisfied, the interview
proceeded with inquiries regarding exclusion criteria.
Exclusion criteria were developed based on elimination of factors that may impact
bone health, quality of life measures, or were of safety concern. Women taking any
medication that could potentially alter bone turnover markers were excluded. These
medications included hormone therapy or hormonal birth control, prescription
medications for thinning bones (current or within past three months), and chronic use of
steroid medications (current or within past six months) as glucocorticoid use can cause
secondary osteoporosis.111 Women with a diagnosis of osteoporosis were excluded
because we wanted to examine the effects of melatonin on bone in healthy women.
Current smokers were excluded as smoking has been associated with decreases in bone
mineral density112 and may impact bone marker status. Hyperparathyroidism is an over
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abundance of PTH, which can greatly alter bone turnover; therefore, women with this
condition were excluded from participation. Women with multiple myeloma or other
cancers were excluded as these diseases can impact bone metabolism and may impact
bone turnover markers, especially if the cancer metastasizes to the bone. Other exclusion
criteria included use of sleep medication or antidepressants due to effects on quality of
life endpoints such as sleep quality and mood. Women with severe sleep apnea or
chronic obstructive pulmonary disease were not eligible to participate as these conditions
can impact sleep quality and may influence sleep endpoints in the study. Women with
uncontrolled high blood pressure or those currently taking medication for blood pressure
were excluded due to safety concerns as melatonin has antihypertensive effects.113 Liver
disease was an exclusion criterion because liver impairment may interfere with the
bioavailability of orally administered melatonin. Women with severe lactose intolerance
were not eligible because all study medication was compounded with lactose.
Those women deemed eligible to participate were asked to schedule an initial
visit to the Center for Pharmacy Care at Duquesne University. Potential participants
were sent an information packet before their first visit including a welcome letter,
directions, a map to the Center for Pharmacy Care, a brochure about bone density testing,
an information sheet, and a copy of the informed consent form. The information sheet
contained answers to questions potential subject may have including what to expect at
their visit, where to park, and how to contact the study team. The information packet was
provided to alleviate participant concerns about the study visit and to encourage study
participation. Participants were given the informed consent form prior to enrollment to
allow women adequate time to read and understand the document.
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At the first

appointment, participants were screened for bone health using the Achilles Insight
ultrasonometer (GE Healthcare). Women with a T-score less than -2.0 were not enrolled
in the study and were advised to follow-up with their primary care physician. Three
blood pressure readings were also taken to ensure the participant had an average blood
pressure below 140/90 and above 100/60. Women fulfilling the bone density and blood
pressure requirements were asked to enroll in the study. Informed consent was obtained
from all study participants. This study was approved by the Duquesne University
Institutional Review Board.

Randomization, Blinding, Allocation Concealment, and Treatment
Randomization: A total of 20 perimenopausal women were desired for this study.
An initial power analysis calculated with a sample size of 10 per group, our study would
have 80% power to detect an estimated difference in serum bone markers between groups
of 0.89. The sample sizes were modified after a research team meeting with all
investigators. As this was a pilot study and we were primarily interested in how
melatonin induces changes over six months, the decision was made to randomize more
individuals in the treatment group (3:1 ratio of treatment to placebo). This distribution
would allow us to obtain an estimate of the effect of the treatment as precisely as
possible. Enrolled participants were assigned to receive either placebo (n = 5) or 3 mg
melatonin (n=15) treatment based on a computer generated randomization scheme. The
actual group assignment was performed using a computerized random number generator.
Blinding: In the informed consent form, subjects were told they would be
randomized to one of two treatment groups. Subjects were blinded as to which treatment
group they were assigned. Additionally, principal and co-investigators had no knowledge
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of group assignments throughout the study period, thus ensuring a double-blinded design.
Investigators were unblinded after all participants had completed follow-up and analysis
had been performed.
Allocation Concealment: Steps taken to ensure allocation concealment consisted
of the primary and co-investigators having no knowledge of the next treatment
assignment for each subject. The total time to recruit study groups was approximately
eighteen months. The research coordinator kept the study subject identification number
and their group assignment in a secure location. Only the research coordinator was
privileged to this information as subjects entered the study. Additionally, since the
primary outcome was a numerical measurement obtained from a blood sample, there was
no bias with respect to the research coordinator knowing the assignment.
Treatment: Identical placebo and melatonin capsules (Figure 4) were formulated
using lactose or 3 mg melatonin in lactose respectively and packaged into individual 30day blister packs by Avalon Pharmacy (Avalon, PA).

Figure 4: Study medication in identical blister packs.
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Compounding of capsules was necessary to keep the formulation consistent between
placebo and melatonin capsule as well as ensures the placebo contained identical
ingredients with the exception of melatonin. Three milligrams is the commonly available
supplemental dose of melatonin in the United States. There is no precedence for what
dose of melatonin is necessary for effects on bone; therefore, a 3 mg dose was selected
because it is capable of producing a measurable physiological response as evidenced by
phase shifts in circadian rhythm with 3 mg oral tablets.110 The timing of the dose was
chosen because melatonin will not cause a significant phase shift in circadian rhythm if
taken at a subject‟s usual bedtime.110
Enrolled study participants were asked to commit to monthly visits to the Center
for Pharmacy Care over a six month period for a total of seven visits (months 0, 1, 2,
etc.). Serum markers of bone metabolism show significant changes in approximately 3-6
months in women taking bisphosphonates32 or teriparatide33 for osteoporosis; therefore,
we felt six months would be a adequate time period to detect changes in markers of bone
turnover with melatonin. During the baseline visit (month 0), subjects were asked to
complete forms detailing basic demographic information as well as listing all regular
prescription and non-prescription drug and/or supplement use. Participants were given a
one-month supply of study medication and were instructed to take one pill approximately
two hours before bedtime. A daily journal was also provided to collect information
regarding compliance, sleep duration, menstrual cycling, physical activity, and any other
information the participant deemed relevant to how she was feeling. Participants were
asked to bring their empty pill pack as well as their completed diary pages to the next
study visit. Diary pages were color-coded by month to facilitate return of completed
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portions at each study visit. Empty blister packs were utilized to track compliance with
taking study medication. At each monthly visit, three blood pressure readings were
obtained by the study nurse to ensure melatonin did not adversely impact blood pressure.
Participants were also asked to report any adverse effects at each visit.

Assessment of Bone Density
Bone density was measured monthly by ultrasound of the os calcis (heel) using
the Achilles InSight ultrasonometer (GE Healthcare, Waukesha, WI). Participants were
asked to place their bare foot between the ultrasound membranes. Measurements were
taken on the non-dominant foot (e.g. measurement of the left foot in a right-hand
dominant person) to account for possible differences in bone density that may result from
favoring the dominant foot. The assessment area was sprayed with ethanol to thoroughly
wet the foot and membranes to ensure proper signal transduction. During measurement,
the membranes filled with warm water to completely surround the subject‟s heel. Results
were reported as T-scores, a measure of how many standard deviations the ultrasound
reading of the participant compares to the reading of a healthy young adult at peak bone
mass. A positive T-score indicates bone density above a young adult; a negative T-score
indicates bone density less than a young adult. Changes to bone density as measured by
ultrasound can take up to a year or more to be detectable. Therefore, monthly changes in
bone density were not expected, and only the month 0 and month 6 measurements were
used in analyses.

Collection and Storage of Serum Samples
Serum samples were collected bimonthly (months 0, 2, 4, and 6) during daytime
study appointments. Participants were not required to fast. Blood was obtained by the
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study nurse via venous puncture using a BD Vacutainer Safety-Lok blood collection set
with a 23 gauge needle. Samples were collected in 8.5 ml BD Vacutainer SST Plus blood
collection tubes. Blood was allowed to clot for at least 30 minutes at room temperature
before centrifugation at approximately 1200 x g for 15 minutes. Serum was removed
from separating gel, aliquoted, and stored at -20˚C until use.

Assessment of Bone Turnover Markers (BTMs)
In order to investigate changes in bone metabolism, two markers of bone turnover
were measured in serum taken at months 0, 2, 4 and 6. Osteocalcin was measured using
the N-MID® Osteocalcin enzyme-linked immunosorbent assay (Immunodiagnostics
Systems, Fountain Hills, AZ) to monitor formation of new bone by osteoblasts. The
osteoclast marker, amino-terminal cross-linking telopeptide of type I collagen (NTX),
was used as an indicator of bone resorption. NTX levels were determined using the
Osteomark® NTx serum enzyme immunoassay (Inverness Medical, Princeton, NJ).
Procedures were carried out according to the manufacturers‟ instructions.
Osteocalcin was measured to determine how melatonin treatment affected bone
formation. Serum samples were pipetted into individual microplate wells precoated with
streptavidin. Two monoclonal human antibodies against osteocalcin – one biotinylated
and one peroxidase conjugated – were added to each well and incubated with the sample
for two hours. Each antibody recognizes a different amino acid portion of osteocalcin.
Osteocalcin in the sample is captured and held to the microplate well by interaction with
the antibodies. After a series of washes, a chromogenic agent was added to produce a
color in the presence of antibody-bound osteocalcin. The absorbance of each well was
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measured to determine the concentration of osteocalcin present. Samples with more
osteocalcin had higher absorbance values.
NTX was measured to determine if melatonin had an impact on bone resorption.
Serum samples were added to microplate wells containing an adsorbed NTX epitope. A
horseradish peroxidase conjugated monoclonal antibody was added to each well. NTX in
serum samples competes with the adsorbed NTX for binding sites on the antibody. After
incubation, a series of washes were performed to remove unbound sample and NTX in
the sample bound to the antibody. A chromogenic agent was added to detect the amount
of antibody bound to NTX on the microplate well. The absorbance of each well was
measured to determine the concentration of NTX in each sample. A decrease in
absorption value indicated a higher serum NTX level.
Concentrations of osteocalcin and NTX were determined using the Perkin Elmer
Victor3 1420 Multilabel plate reader with Workout 2.0 software (Waltham, MA).
Absorbance readings of standards, controls, and subject samples were measured at 450
nm for both the osteocalcin and NTX immunoassays. A standard curve was generated for
each assay using the four parameter logistic curve fit function as recommended by each
assay protocol. Sample concentrations were calculated by Workout 2.0 software based
on the generated standard curves. Figure 5 illustrates sample standard curves from both
the osteocalcin and NTX immunoassay. Additional standard curves can be found in
Appendix A.
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Figure 5: Sample immunoassay standard curves

Serum Melatonin Levels
In order to determine whether baseline melatonin levels were related to treatment
outcome, daytime serum melatonin levels were measured for each participant using blood
samples taken at the baseline visit. Melatonin was also measured at the end of the sixmonth study to observe any changes in melatonin levels with treatment. Serum samples
were analyzed using the melatonin direct radioimmunoassay kit (IBL International,
Toronto, ON). The assay was carried out according to the manufacturer‟s instructions.
Briefly, serum samples were combined with melatonin 125I-Tracer and a polyclonal
melatonin antibody. After overnight incubation, precipitating antiserum was added and
tubes were centrifuged to pellet the precipitate. All liquid was removed via vacuum
aspiration. The amount of radioactivity in each tube was assessed using the Perkin Elmer
Packard Cobra II Auto-Gamma 5000 Series gamma counter to obtain counts per minute
(cpm). The cpm value for non-specific binding (NSB) was subtracted from all other cpm
values. The percentage of binding in each tube compared to the 0 pg/ml control tube (Bo)
was calculated to obtain the (B/Bo) % value using the equation:
𝑐𝑝𝑚𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑐𝑝𝑚𝑁𝑆𝐵
𝐵
%=
× 100
𝐵𝑜
𝑐𝑝𝑚𝐵𝑜 − 𝑐𝑝𝑚𝑁𝑆𝐵
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A standard curve ranging from 2.5 – 750 pg/ml was generated using a nonlinear curve fit
algorithm for one site competitive binding assays (Figure 6, GraphPad Prism version
5.01). Melatonin serum concentrations were determined by taking the antilog of the log
melatonin concentration corresponding to the sample (B/Bo) % value on the standard
curve. Samples with levels below the limit of detection (< 2.5 pg/ml) were assigned a
value of 2.5 pg/ml.
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Figure 6: Melatonin RIA standard curve. A standard curve was generated by plotting (B/Bo) %
versus the log of the melatonin concentration for each standard. Standard concentrations
ranged from 2.5 pg/ml to 750 pg/ml melatonin.

Menopausal Quality of Life
Participants were asked to complete the Menopause-Specific Quality of Life –
Intervention (MENQOL) questionnaire114 at both the initial and final study visits. This
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validated questionnaire consists of 32 menopausal symptoms divided into four domains:
vasomotor, psychosocial, physical, and sexual. The full questionnaire is reproduced at
the end of the Methods section. Subjects were asked to indicate if they experienced a
specific symptom and, if so, to rate how bothered they were on a scale of 0 (not bothered)
to 6 (extremely bothered). Questionnaires were scored according to established
guidelines to obtain scores for each of the four domains.114, 115 Briefly, each survey item
was scored on scale of 1 to 8 with 1 corresponding to a “no” answer regarding the
symptom and 8 corresponding to an answer of “yes” with the maximum “bothered
rating” of 6. Domain scores were obtained by calculating the mean of all item scores
within that particular domain. The vasomotor domain was composed of items 1-3. The
psychosocial domain included items 4-10. Items 11-26 and 30-32 made up the physical
domain. The sexual domain consisted of items 27-29. Missing or incomplete data were
handled as described.114, 115 If an entire item was missed on the month 0 questionnaire,
the imputed score for that item was determined as the mean of the item score for all
participants who responded. This situation was encountered on one survey throughout
the study. If the missing item score was on the month 6 questionnaire, then the missing
value was calculated as the mean of the item score from all participants in the subject‟s
treatment group. Incomplete items occurred when a “yes” was indicated but no rating
was checked. For this situation, the item score was determined by calculating the mean
of the “bothered” ratings from all other “yes” answers within the domain on the subject‟s
own survey. Incomplete items occurred on only two surveys, one at month 0 and one at
month 6 from two different subjects. Differences in domain scores between month 0 and
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month 6 were calculated for each participant. Differences in domain scores were
compared between the placebo and melatonin treatment groups.

Sleep Quality
The Pittsburgh Sleep Quality Index (PSQI) survey116 was administered to
participants at the month 0 and month 6 study visits to determine the effect of melatonin
treatment on sleep. The PSQI is a validated questionnaire used to distinguish between
“good” and “poor” sleepers.116 Participants answered a series of questions from seven
categories which determine overall sleep quality – subjective sleep quality, sleep latency,
sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication,
and daytime dysfunction. Questionnaires were scored according to published guidelines
to obtain a global PSQI score ranging from 0 to 21, with a higher score indicating
difficulty in multiple areas affecting sleep quality.116 Differences in global PSQI scores
from month 0 to month 6 were calculated for each individual. Mean differences were
compared between treatment groups.

Daily Diary
Participants were given a daily journal to capture information about compliance,
use of prescription and non-prescription medications, the number of hours slept each
night, menstrual cycling, exercise, and feelings of well-being. Journal entries were
utilized to assess changes in menstrual cycling over the course of the study. Each day
women were asked to indicate if their period began or ended. Women were excluded
from analysis if diaries were not complete enough to determine length of period, number
of periods, or both. Two women were excluded from all evaluations of menstrual
cycling. One woman was diagnosed with uterine fibroids, and the other subject had
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sustained episodes of heavy bleeding such that cycling was not evident in diary
information. Journals were also used to estimate the average number of hours slept each
month for each participant. Missing values were estimated using mean replacement. The
number of nights in which sleep disturbances were recorded by each individual was also
examined.

Statistical Analysis
Descriptive statistics (means, medians, standard deviations, and various frequency
distributions) were used throughout the dissertation to describe the variables collected.
To check the randomization was effective, a comparisons of the baseline characteristics
between placebo and melatonin participants was performed using Student‟s t-test for
independent samples (continuous data) and Fishers exact test (categorical data).
Treatment differences in continuous variables measured at month 0 and month 6 were
analyzed by first calculating the difference between the times for each individual and
these individual differences were compared between treatment groups using Student‟s ttest with Welch‟s correction. This test is equivalent to performing a mixed models
analysis with group (fixed effect), subject nested within group (random effect), time
(fixed effect) and time by group interaction (fixed) terms in the model and testing the
group term within the model. Similarly, continuous variables with repeated measures
over time (0, 2, 4, and 6 months) were also analyzed using mixed effects analysis of
variance (except time was considered random). Means between groups at each time point
were tested using Tukey‟s HSD post-hoc multiple comparison procedure. Statistical
testing was carried out using GraphPad Prism version 5.01 for Windows (GraphPad
Software, San Diego, CA) and JMP versions 8 and 9 (SAS Institute Inc, Cary, NC).
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Results were considered significant at p < 0.05. Analysis was performed using the
intention-to-treat principle.
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MENQOL Questionnaire
Reprinted from Maturitas, 50(3), Lewis JE, Hilditch JR, Wong CJ, Further psychometric
property development of the Menopause-Specific Quality of Life questionnaire and
development of a modified version, MENQOL-Intervention questionnaire, pp 209-221,
Copyright 2005, with permission from Elsevier.
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MENQOL Questionnarie continued
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Pittsburgh Sleep Quality Index
Reprinted from Psychiatry Research, 28(2), Buysse DJ, Reynolds CF, 3rd, Monk TH,
Berman SR, Kupfer DJ, The Pittsburgh Sleep Quality Index: a new instrument for
psychiatric practice and research, pp 193-213, Copyright 1989, with permission from
Elsevier.
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Pittsburgh Sleep Quality Index continued

59

RESULTS
Specific Aim One
The effectiveness of the various recruitment strategies we employed are shown in
Table 1. In terms of generating interest in the study, the article published in the
Pittsburgh Tribune-Review117 on Monday, March 23, 2009 was the most effective;
however, none of the women who responded to this article were ultimately enrolled in the
study. The low enrollment from this method of advertisement may be due to ambiguity
in the article itself, which resulted in more postmenopausal women responding than
perimenopausal women. The majority of enrolled participants were recruited through
advertisements aimed at the Duquesne University community and by word-of-mouth.
Table 1: Effectiveness of Recruitment Strategies
Method of Recruitment
DU Alumni Magazine article
DU Daily
DU Newspaper article
Flyer
Newspaper Advertisements
South Hills Almanac article
South Pittsburgh Reporter
Tribune-Review article
Word-of-mouth
Other
Unknown
DU: Duquesne University

Number of
Inquires
9
13
1
6
6
5
3
20
13
2
19

Number Enrolled
in Study
3
3
0
1
3
3
0
0
6
0
0

The results of the recruitment and enrollment processes are illustrated in Figure 7.
Of the 97 respondents, 82 (84.5%) were reached for a phone screening. Of those
completing the phone interview, 34% did not meet the inclusion criteria of being
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perimenopausal and 22% were not eligible based on exclusion criteria. The three most
common reasons for exclusion we encountered were use of medication for depression or
anxiety (33% of those excluded), being a current smoker (33%), and use of hormone
replacement therapy or hormonal contraceptives (22%). Perhaps the largest obstacle
faced during recruitment and enrollment were the 13 women who were eligible for the
study but for their own reasons chose not to participate. The most common reason for not
enrolling was lack of time and not being able to commit to the monthly visits over the six
month study period. Information regarding the sample population utilized in this study is
provided in Table 2.
Table 2: Sample population characteristics
Mean ± SD

Range

Age (years)

49.5 ± 3.0

45.1 – 54.5

2

BMI (kg/m )

24.6 ± 4.0

17.9 – 31.1

Serum Melatonin (pg/ml)
Serum Osteocalcin
(ng/ml)
Serum NTX (nM BCE)

26.8 ± 24.9

2.5 – 75.9

12.3 ± 3.9

3.8 – 18.4

12.3 ± 4.1

6.1 – 19.3

-0.5 ± 1.0

-1.8 – 1.6

72% (13/18)

N/A

Vasomotor

2.2 ± 1.2

1.0 – 4.7

Psychosocial

3.2 ± 1.4

1 .0 – 5.9

Physical

2.8 ± 1.2

1.2 – 4.9

Sexual

2.4 ± 2.2

1.0 – 8.0

5.1 ± 2.6

1 .0 – 11.0

T-score (calcaneus)
Vitamin Supplementation
MENQOL

PSQI

Mean ± SD; n = 18; BMI, body mass index based on patientreported height and weight; NTX, amino-terminal crosslinking telopeptide of type I collagen; BCE, bone collagen
equivalents; MENQOL, Menopause-Specific Quality of Life;
PSQI Pittsburgh Sleep Quality Index
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Figure 7: Flow of recruitment and enrollment. A total of 97 women responded to
advertisements. Nineteen women were randomized, but one woman in the melatonin
group withdrew after only two days in the study. A total of 5 women in the placebo
group and 13 women in the melatonin group were included in all analyses. ITT,
intention-to-treat
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Specific Aim Two
Out of 97 respondents, a total of 19 women were initially enrolled in the study;
however, one subject withdrew after two days. The subject refused to participate in the
study, and since no follow-up data was obtained, the principal investigator decided this
individual would be removed and not considered part of the study. Thus, the intentionto-treat analysis consisted of five women in the placebo group (all with complete followup) and thirteen women in the treatment group (all with complete follow-up). All women
self-identified as Caucasian and ranged in age from 45-54.5 years. Baseline differences
between groups are illustrated in Table 3. Subjects in the melatonin group were
significantly older compared to placebo subjects (50.3 vs 47.5, respectively). The age
difference may not be clinically relevant as there is no set age for the perimenopausal
stage. The stage of perimenopause (early versus late) may be a more important factor
than age. Older women may show biological differences such as more menopausal
symptoms if they are in a later stage of perimenopausal. As may be expected with an
older perimenopausal population, MENQOL vasomotor domain scores, including items
such as hot flashes, were also significantly higher at baseline in the melatonin group (2.5
vs 1.3). All other variables were not significantly different between groups.
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Table 3: Baseline characteristics
Placebo
(n=5)

Melatonin
(n=13)

Age (years)

47.5 ± 2.0(45.4 – 50.7)

50.3 ± 3.0 (45.1 – 54.5)*

2

BMI (kg/m )

21.7 ± 3.5 (17.9 – 26.9)

25.7 ± 3.7 (18.2 – 31.1)

Serum Melatonin (pg/ml)
Serum Osteocalcin
(ng/ml)
Serum NTX (nM BCE)

41.9 ± 27.5 (2.5 – 75.9)

21.1 ± 22.3 (2.5 – 70.8)

14.1 ± 3.9 (9.5 – 18.4)

11.6 ± 3.8 (3.8 – 17.6)

12.0 ± 4.4 (6.1 – 16.4)

12.4 ± 4.2 (7.3 – 19.3)

-0.8 ± 0.8 (-1.8 – 0.1)

-0.4 ± 1.1 (-1.5 – 1.6)

80% (4/5)

69% (9/13)

Vasomotor

1.3 ± 0.8 (1.0 – 2.7)

2.5 ± 1.3 (1.0 – 4.7)*

Psychosocial

2.9 ± 0.8 (1.9 – 3.9)

3.3 ± 1.6 (1.0 – 5.9)

Physical

2.0 ± 0.9 (1.3 – 3.6)

3.1 ± 1.2 (1.2 – 4.9)

Sexual

2.0 ± 1.4 (1.0 – 4.3)

2.6 ± 2.4 (1.0 – 8.0)

5.0 ± 1.0 (4.0 – 6.0)

5.2 ± 3.0 (1.0 – 11.0)

T-score (calcaneus)
Vitamin Supplementation
MENQOL

PSQI

Mean ± SD (Range); BMI, body mass index based on patient-reported height and weight;
BCE, bone collagen equivalents; MENQOL, Menopause-Specific Quality of Life; PSQI
Pittsburgh Sleep Quality Index; * p < 0.05, t-test with Welch’s correction

Over the course of the six month study period, bone health was monitored using two
different methods. Changes in bone density were measured monthly at the calcaneus
using the Achilles InSight ultrasound machine (Figure 8). Participants in the placebo
group had an average T-score change of -0.02 over six months. Women in the melatonin
group had an average change of 0.05. A more positive T-score indicates an improvement
in bone density. Melatonin treatment had no significant effect on changes in bone
density over the 6 month study period. Appreciable changes in bone density are often not
seen until completion of one to two years of treatment; therefore, it would be expected
that any effect of melatonin on BMD may not be observable at this early time point. Bone
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mineral density T-scores for each individual over the study period can be found in
Appendix B.
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Figure 8: Bone mineral density changes over six month study. Mean ± SEM; Change
from baseline calculated for each individual. Mean changes between placebo and
melatonin compared using t-test with Welch’s correction, p < 0.05; n = 5 placebo, n = 13
melatonin.

In addition to bone density, markers of bone metabolism were measured in serum
samples collected bimonthly (months 0, 2, 4, and 6) via venous puncture. The osteoclast
marker, amino-terminal cross-linking telopeptide of type I collagen (NTX), was used as
an indicator of bone breakdown. Osteocalcin was measured to monitor formation of new
bone by osteoblasts. Both of these markers have been measured in perimenopausal
women.8, 9, 14, 35 Additionally, they were stable enough to be stored for assay at a later
date; due to our rolling recruitment, samples were not always run immediately but were
frozen until enough samples were collected to complete a full immunoassay plate.
Changes in bone turnover markers in response to bisphosphonates can be seen as early as
three months32; therefore, these markers may provide information about the effect of
melatonin on bone at an earlier time than ultrasound. Figure 9 illustrates the changes in
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bone turnover markers for both placebo and melatonin treatment groups. No significant
treatment effects were found over time using mixed models analyses for either
osteocalcin or NTX. Graphs illustrating the changes in bone markers for each participant
can be found in Appendix B.
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Figure 9: Serum osteocalcin and NTX levels over six month study period. (A) serum
osteocalcin (B) serum NTX. n = 5 placebo, n = 13 melatonin. Data expressed as mean ± SEM.
At all time points, differences between treatment groups were non-significant for each bone
marker as determined by mixed model analyses.

The remodeling and maintenance of bone is a tightly coupled process that requires
a balance in osteoclast and osteoblast activities such that breakdown of old bone is
coupled with formation of new bone. Current therapies, with the exception of the
anabolic agent teriparatide, work by inhibiting osteoclasts to slow breakdown of bone.22,
27

Melatonin is unlike standard osteoporosis therapies in that it has the potential to both

stimulate osteoblasts46, 60 as well as inhibit osteoclast activity.63 Due to its unique action
on bone, we wanted to examine the coupling between osteoclast and osteoblast activity in
each treatment group. Figure 10 illustrates the changes in osteocalcin and NTX levels
over time for the placebo (panel A) and melatonin (panel B) treatment groups. Panel C
of Figure 10 shows how the ratio of osteoclast activity to osteoblast activity (expressed at
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the ratio of NTX to osteocalcin levels) changes over the study period. Ratios in the
melatonin group appear to be trending towards one over time, possibly indicating a more
even balance between osteoclast and osteoblast activity as seen in premenopausal
women. Also interesting to note is the slight increase in osteocalcin from month 0 to
month 2 with melatonin treatment that continued throughout the duration of the study.
Also interesting is the slight downward trend of NTX after the two-month timepoint.
This pattern is not seen in the placebo group. Thought it is difficult to draw conclusions
based on the small sample size, it is possible that melatonin may induce an increase in
osteoblast activity, improving bone marker status in perimenopausal women. This idea is
also supported by Figure 10C which reveals a time-dependent trend towards an NTX:OC
ratio of 1:1 in the melatonin treatment group. Future studies should examine multiple
markers of osteoblast activity such as bone-specific alkaline phosphatase to determine if
the same pattern occurs in a larger population and with additional bone markers.
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Figure 10: Ratio of bone turnover markers by treatment group. (A) Osteocalcin (left axis) and
NTX (right axis) levels for placebo group (n = 5) (B) Osteocalcin (left axis) and NTX (right axis)
levels for melatonin group (n = 13). Data expressed as mean ± SEM. (C) Ratio of osteoclast to
osteoblast activity calculated as the ratio of NTX to osteocalcin serum levels. Bars within each
month indicate mean.

Daytime serum melatonin levels were assessed at month 0 to determine if
endogenous melatonin levels predicted a response to melatonin treatment as one previous
study found a relationship between endogenous melatonin peak levels and response to
exogenous supplementation for sleep.118 Month 6 melatonin levels were measured to
detect changes in melatonin levels after treatment. Figure 11 shows the raw data for the
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measurement of daytime serum melatonin levels. Several samples, particularly in the
melatonin treatment group, were below the limit of detection. Values varied widely at
both months 0 and 6, ranging from undetectable to 75 pg/ml.

When undetectable

samples were assigned a value of 2.5 pg/ml (the limit of detection), the mean (± standard
deviation) baseline serum melatonin levels for the placebo and melatonin groups were
41.9 ± 27.5 pg/ml and 21.1 ± 22.3 pg/ml, respectively. Median values at baseline were
49.0 pg/ml in the placebo group and 13.2 pg/ml in the melatonin group. After the six
month study period, mean values were 37.1 ± 23.0 pg/ml in the placebo group and 20.1 ±
26.6 pg/ml in the melatonin group. Median values for placebo and melatonin groups at
month 6 were 43.7 pg/ml and 2.5 pg/ml, respectively. There is variability in what value to
assign samples with levels below the limit of detection. Options could include assigning
a value of zero, using the limit of detection measure, or choosing the value midway
between. Due to the number of undetectable samples, it may be inappropriate to perform
statistical analysis. Looking at the data by individual person (Appendix B), six subjects
in the melatonin group had serum levels below the limit of detection at both baseline and
month 6 time points. Of the five remaining subjects in the melatonin group, three had
values decrease between baseline and month 6 follow-up while two subjects had an
increase from baseline to month 6. Overall, it does not appear that melatonin treatment
had an effect on daytime serum melatonin levels. Baseline daytime melatonin levels did
not appear to predict the degree of bone marker changes; however, daytime melatonin
levels may not reflect the peak level of melatonin secreted at nighttime. A 24-hour
melatonin profile would be necessary to fully assess a relationship between melatonin
levels and degree of response to treatment.
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Figure 11: Daytime serum melatonin levels. Serum melatonin levels were determined at
months 0 (baseline) and 6 by radioimmunoassay. Several samples had levels below the limit
of detection (< 2.5 pg/ml) and are indicated by the  symbol.

The MENQOL-Intervention survey was administered at month 0 and month 6 to
determine the impact of melatonin supplementation on menopausal symptoms.
MENQOL vasomotor, psychosocial, and sexual domain scores did not change
significantly with melatonin treatment; however, participants taking melatonin had
significant improvement in their MENQOL physical domain scores (Table 4) compared
to those in the placebo group (-0.6 vs 0.1, respectively). The decrease in MENQOL
physical domain score indicates an improvement in physical symptoms with melatonin
treatment. Items included in the physical domain included feeling tired or worn out,
difficulty sleeping, breast pain, and vaginal bleeding or spotting.
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Table 4: Change in MENQOL and PSQI scores after treatment with melatonin or placebo
Placebo
n=5
Baseline Month 6

Change

Melatonin
n = 13
Baseline Month 6
Change

MENQOL
Vasomotor
1.3
1.1
-0.2 (0.4)
2.5
2.9
+0.4 (1.8)
Psychosocial
2.9
2.7
-0.2 (1.3)
3.3
2.9
-0.4 (1.3)
Physical
2.0
2.1
+0.1 (0.5)
3.1
2.5
-0.6 (0.8)*
Sexual
2.0
1.3
-0.7 (1.4)
2.6
2.2
-0.4 (1.2)
PSQI
5.0
4.0
-1.0 (1.4)
5.2
4.7
-0.5 (2.8)
Mean (SD); MENQOL, Menopause-Specific Quality of Life; PSQI Pittsburgh Sleep Quality
Index; * p < 0.05, t-test with Welch’s correction

Information in participant diaries was examined to continue exploring the effect of
melatonin on physical aspects of the menopausal transition. Menstrual cycle patterns
over the six month study period were charted based on information reported in daily
diaries. Women were excluded from analysis if diaries were not complete enough to
determine duration of period, number of periods, or both. Two women were excluded
from all evaluations of menstrual cycling. One woman was diagnosed with uterine
fibroids, and the other subject had sustained episodes of heavy bleeding such that cycling
was not evident in diary information. Women in the melatonin group reported
significantly fewer periods during the six month study (Figure 12A) compared to those
subjects in the placebo group (4.3 ± 0.6, n = 10 melatonin vs 6.5 ± 0.3, n =4 placebo;
mean ± SEM) and a correspondingly higher number of days between periods (Figure
12B; 51.2 ± 11.4, n = 10 melatonin; 24.1 ± 0.9, n = 4 placebo), suggesting melatonin may
influence menstrual bleeding patterns in perimenopausal women. Average duration of
menstrual periods was not different between treatment groups (Figure 12C).
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Figure 12: Menstrual cycling differences between treatment groups. Based on menstrual
cycles recorded in subject diaries, subjects receiving melatonin reported significantly fewer
periods (A; 4.3 ± 0.6, n = 10 melatonin vs 6.5 ± 0.3, n =4 placebo; mean ± SEM; p < 0.05)
and a greater number of days between periods (B; 51.2 ± 11.4, n = 10 melatonin; 24.1 ±
0.9, n = 4 placebo; p < 0.05). There was no significant difference in the average length of
periods between treatment groups (C; 5.9 ± 0.5, n = 9 melatonin; 6.7 ± 0.8, n = 3 placebo; p
> 0.05).

The PSQI survey was administered to participants to assess the impact of
melatonin treatment on sleep quality. The results of the PSQI survey did not capture a
relationship between melatonin administration and improvement in overall sleep quality
(Table 4). As part of the daily diaries, participants were also asked to record the number
of hours of sleep they received each night. Analysis of participant diaries showed no
significant impact on nightly duration of sleep (Figure 13); however, there appeared to be
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less variability in the melatonin group. This could be due to the higher number of
participants in the melatonin group, or melatonin may be regulating their sleep-wake
patterns. Several subjects also recorded incidents of nighttime disturbances or
interruptions; one subject in the melatonin group kept extremely detailed records about
nighttime disturbances (Figure 13B). Recording sleep interruptions, however, was not a
specific entry requested in the daily journal. Therefore, we were unable to determine
treatment effects on sleep disturbances because not all participants provided this
information.
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Figure 13: The impact of melatonin on sleep patterns. A. The number of hours slept each night
was recorded in subject diaries. Analysis using mixed model analysis of variance showed no
significant changes with melatonin treatment (p > 0.05); n = 5 placebo; n = 13 melatonin. B.
Example of participant tracking the number of nighttime interruptions. Melatonin appears to
decrease disturbances over the study period.

Although there was no significant difference in PSQI scores with melatonin
treatment, many participants reported stated they were sleeping better indicating an
improvement in sleep quality. In fact, 61.5% (8 out of 13) of subjects given melatonin
were able to correctly identify their treatment group. When asked why they thought they
were given melatonin, subjects reported reasons such as feeling better and sleeping better.
Only 15% of melatonin subjects (2 out of 13) incorrectly identified the treatment group.
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For those in the placebo group, 60% of subjects (3 out of 5) correctly identified their
treatment group based on no change in sleep or relief of menopausal symptoms and 20%
(1 out of 5) incorrectly identified their treatment group; the remaining placebo subject
was undecided. These results suggest melatonin may be improving some aspect of wellbeing that could include more regular sleep patterns or improved quality of sleep;
however, a larger trial that analyzes specific aspects of sleep quality would be necessary.
Blood pressure was assessed at each monthly visit to detect alterations in blood
pressure with treatment. The average of three measurements was recorded. As seen in
Table 5 and Figure 14, there appears to be a downward trend in blood pressure readings
in both the placebo and melatonin group, possibly indicating more comfort with the study
procedures as time progressed. Interesting to note is the change in systolic pressure with
melatonin treatment (Table 5; Figure 14B) which appears to show an even greater
decrease than with placebo treatment. Treatment with melatonin does not negatively
impact blood pressure in our study samples and, in fact, appears to lower blood pressure.
Individual blood pressure changes at each month can be found in Appendix B.
Table 5: Changes in blood pressure after treatment with melatonin or placebo

Baseline
118.0

Placebo
n=5
Month 6
115.0

Change
-3.0 (7.8)

Baseline
117.3

Melatonin
n = 13
Month 6
Change
111.3
-6.0 (12.7)

Systolic Pressure
(mmHg)
Diastolic Pressure
76.4
70.6
-5.8 (5.3)
75.5
70.0
-5.5 (6.1)
(mmHg)
Pulse Pressure
41.6
44.4
2.8 (5.0)
41.8
41.3
-0.5 (10.3)
(mmHg)
Mean (SD); No significant differences between groups found using t-test with Welch’s
correction
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Figure 14: Blood pressure readings after study period. The mean of three blood pressure
measurements is displayed for each participant at baseline and after six months. There was an
overall decrease in both diastolic and systolic pressure over the study period in both treatment
groups. The decrease in systolic pressure appears to be more dramatic with melatonin
treatment.
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DISCUSSION
The first aim of this study was to assess the feasibility of recruiting
perimenopausal women willing to participate in a clinical trial of melatonin versus
placebo. An important part of this pilot study was to identify the best strategies for
maximizing interest and subject retention. The recruitment process began in August of
2008 and continued through January of 2010. We successfully enrolled 19 women into
the study out of a total of 97 interested women. Most enrolled participants were recruited
through Duquesne University advertisements, possibly because women were more
willing to enroll in a study at an institution with which they were associated. Word-ofmouth was also an effective strategy in enrolling participants. Perhaps, a personal
account of what the study is about and what enrollment entails made more eligible
women express an interest. Flyers and newspaper advertisements were limited in the
amount of information that could be included. We relied on interested women to call us
for more details. Recruitment avenues that allowed us to express the rationale and aims
for the study were the most effective at generating inquiries about participation. These
strategies included detailed articles in a local neighborhood newspaper (South Hills
Almanac), the Duquesne University alumni magazine, and the Pittsburgh TribuneReview. The Tribune-Review article generated the most phone calls about participation;
however, many women were not eligible because they were not perimenopausal.
Inclusion and exclusion criteria can negatively impact study enrollment rates even
though they are necessary to obtain a specific cohort of study participants. In an article by
Panjari et al. 2008, they describe difficulty in recruiting postmenopausal women in
Australia willing to participate in a randomized, double-blind, placebo-controlled trail of
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oral DHEA.119

Panjari et al. found many women did not qualify as postmenopausal and

were therefore not eligible to participate in their study.119 Many of the ineligible women
in our study did not meet the inclusion criteria for being in perimenopause (34%) despite
the three criteria being stated in our advertisements. Thus, one may speculate the
ambiguity faced clinically in describing various states during the transition through
menopause extends to the lay population as well. Women may not understand the subtle
differences in the terms perimenopause and postmenopause. Many women who did not
meet our inclusion criteria were already postmenopausal and expressed concerns about
being at risk for osteoporosis. The majority of these women heard about our study
through an article written in the Pittsburgh Tribune-Review117. The article discussed
postmenopausal osteoporosis, which may have led primarily postmenopausal women to
express an interest in participation. Perimenopausal women may have thought they were
not through menopause and therefore did not need to or were not eligible to participate in
the study. Women may associate osteoporosis and bone health with menopause, not
realizing bone loss begins to occur before they have their last menstrual period.
Indeed, lack of participation in a prevention trial can become an issue as healthy
subjects often feel they are not in need of a therapy.120 Analysis of trials examining
effective recruitment strategies have demonstrated that increased education about the
intervention and disease state can increase recruitment in randomized trials.121 To
increase recruitment in future studies surrounding bone loss during perimenopause,
educational information about when bone loss occurs in the aging process could be
beneficial. Also, women need to be aware they could be experiencing bone loss without
having symptoms. In this study, eligible women were given a pamphlet in the
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information packet with facts about osteoporosis risk, prevention, and how bone density
is measured by ultrasound. An additional strategy could be the use of a questionnaire
with recruitment materials. Kendrick et al. found that the inclusion of a home safety
questionnaire in recruitment mailings increased enrollment in an injury prevention trial
compared to mailings without a questionnaire.122 Future recruitment materials for a study
of melatonin and bone health could include a questionnaire designed to educate women
on their risk for osteoporosis.
Enrollment difficulties can stem from a variety of situations. In their recruitment
of postmenopausal women, Panjari et al. found approximately 55% of women who were
eligible after a phone screening declined to attend their first study visit. The two most
common reasons for non-participation were the time constraints involved with
participation and wariness of adverse effects.119 In our study, 36% (13 of 36) of eligible
women chose not to attend their initial appointment. As with Panjari et al.119, we found
women were unable or unwilling to make the time commitment or were fearful of
possible side effects with melatonin administration. The time constraints of work and
family obligations may have been factors in the 36% of women who declined to
participate in our study. Most of the women we enrolled were working full-time. Many
women expressed a need for weekend hours if they were going to commit to participate
in the study. Offering Saturday morning hours once a month was a crucial part of our
successful recruitment and retention of participants.
Apprehension over taking an unknown treatment (placebo or study medication)
can lead some people to decline enrollment in a randomized study.120, 123, 124 Interviews
with people who declined participation in a randomized, placebo-controlled study of
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aspirin revealed concerns from one individual about taking a placebo as they were
unclear about what was in the placebo. Another person expressed concerns about not
being given aspirin when eligibility screenings identified them as a candidate for therapy.
In fact, some potential participants opted to go on aspirin therapy themselves without
enrolling to ensure they were on therapy and not placebo.120 During the recruitment
process for our study, one woman asked if she could be placed in the placebo group and
subsequently declined participation because she did not want to be randomized. An
„open‟ trial design in which subjects are aware of their treatment has been suggested as
one method to increase recruitment123, 124; however, the disadvantages to having an
unblinded trial may outweigh the increase in enrollment. Potential study participants also
have concerns about adverse effects from treatment. Educational material about the
intervention may be an additional strategy to prevent eligible subjects from declining
participation. One woman declined to participate after reading material on a website that
claimed melatonin could cause sleepwalking. Two other women expressed concerns
about daytime drowsiness as listed in the potential side effects section of the study
consent form. We tried to address concerns potential participants may have had about
participating in the study by mailing them an informational packet before their first
appointment. We hoped to make the process as simple as possible by providing
directions, phone numbers, and a summary of what the appointment would entail. The
informed consent form was also provided prior to the first appointment to ensure
potential subjects had adequate time to carefully read over the risks and benefits of
participation and come to the appointment with any questions or concerns. Willingness
on behalf of the research staff to discuss any concerns may alleviate apprehension about
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treatment; however, some people may still not feel comfortable taking an unknown
treatment with risks of adverse effects. Several studies have found monetary
incentives121, 123 and telephone calls123, 124 to be effective strategies for increasing
enrollment and retention of study participants. We utilized both of these strategies and
found we were successful in retaining all but one study participant who dropped out very
early in the study. Participants were also compensated ten dollars for each visit and
offered parking validation. Subjects completing the study received an additional fifteen
dollars. Compensation was to make up for the travel expenses associated with each
monthly visit. All participants were called within one week of their appointments as a
reminder; appointments were rescheduled if necessary. Participants were also given
appointment reminder cards at their previous visit with the date and time of their next
appointment. We had one instance where a participant did not attend her monthly
appointment, despite several phone calls. We were able to reach her within a week and
have her come in for her appointment. The high retention rate and low number of missed
appointments illustrate our ability to enroll and retain study participants utilizing these
strategies.
Future studies with a larger sample size may need to employ additional marketing
strategies to increase enrollment and decrease the recruitment time period. Through this
study, we have identified that the most effective advertisements are those in which more
details about the study can be given, including the purpose of the study and the benefits
of the intervention. Future strategies targeting perimenopausal women could include
presentations to local women‟s groups about osteoporosis, articles about the study in
local neighborhood newspapers, and more detailed advertisements in city-wide
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newspapers. Educational information about osteoporosis risk may draw more interest in
study participation, particularly for women who may not think they need to worry about
bone health until they are postmenopausal. Information about melatonin should also be
included to help alleviate fears about adverse effects. All women in enrolled in our study
self-identified as Caucasian. We did not collect information on race from all screened
individuals; therefore, we cannot determine if our recruitment strategies successfully
attracted a diverse population. Nevertheless, efforts should be made in future studies to
enroll a more racial and ethnically diverse population. Strategies to increase diversity
could include advertisements at churches and community centers in areas with high
minority populations. Additional studies should utilize telephone reminders,
compensation for travel expenses, and weekend appointment hours as we found these
strategies to be successful in recruitment, enrollment, and retention.
The second aim of this study was to evaluate the effects of melatonin on bone
health and quality of life. The primary endpoints were measurements of bone health
including assessment of bone density by quantitative ultrasonography and measurement
of bone turnover markers (BTMs) in serum. Quantitative ultrasound results revealed no
significant changes in bone mineral density (BMD) after the six-month study period in
either the placebo or melatonin treatment groups (Figure 8). Ultrasound of peripheral
sites, such as the calcaneus, are similar to DXA scan measurements for the ability to
discriminate between women with and without a history of hip fracture125 and
osteoporotic vertebral fractures.126 However, DXA is still the gold standard method for
diagnosing osteoporosis. Peripheral BMD measurements can be obtained at the heel,
wrist, or finger and have several benefits over DXA including reduced expense,
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portability of the machine, and no exposure to radiation. Bone density measurements at
peripheral sites are often utilized for screening purposes to identify people for which
further examination by DXA are warranted. Although we did not see a significant
change in T-score, this was not an unexpected result. Changes in bone density can take a
year or more to be observed based on the sensitivity of imaging methods. Bone density
measurements provide information about the mass of bone but do not provide
information about the bone microarchitecture or the rate of bone remodeling. The rate at
which bone is being remodeled is important when considering osteoporosis as part of the
disease pathology centers around an imbalance in bone metabolism.11 One way to assess
bone remodeling is to measure biochemical markers of bone turnover. Bone turnover
markers can be measured in serum or urine to provide information about the bone
metabolism on a molecular level. BTMs are also useful for monitoring how the body is
responding to a particular therapy.
In this study, we utilized two markers of bone turnover: osteocalcin to monitor
bone formation and NTX to examine bone resorption or breakdown. As illustrated in
Figure 9, we found no significant changes in OC or NTX over the study period in either
treatment group. BTM expression did not differ between treatment groups at any time
point. In Figure 9, osteocalcin appears to increase from baseline to month 2 with
melatonin treatment. While not significant, this could be an indication of melatonin
stimulating osteoblast activity. With the sample sizes in this study, a difference of 3.2
ng/ml would be necessary to achieve a statistically significant result as determined by
mixed model analysis. A sample size of 35 per group would provide enough participants
to detect a 3.2 ng/ml change in osteocalcin with 90% power at an alpha of 0.05. A larger
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sample size will provide a better understanding of the ability of melatonin to alter BTM
levels in perimenopausal women. Although there were no significant changes in BTMs,
there was a downward trend in the ratio of NTX to OC with melatonin treatment (Figure
10C). The action of bone-resorbing osteoclasts and bone-forming osteoblasts are tightly
coupled. Osteoporosis is be caused by a disruption in the balance of bone metabolism
such that the action of osteoclasts outpaces osteoblasts, leading to a net loss of bone.11
The ratio of a bone resorption marker to bone formation marker could provide
information about the coupling between osteoclast and osteoblast activity. We examined
the ratio of NTX to OC and found a trend toward a ratio of 1.0 in the melatonin group.
Although the individual BTMs measured were not different between treatment group, the
downward trend in NTX:OC ratio with treatment indicates melatonin may possibly work
to balance the activity of osteoclasts and osteoblasts.
Serum melatonin levels were measured at baseline to determine if they could
predict a response to treatment. In a study of the effects of melatonin on sleep and
activity in subjects with brain disorders, Laakso et al. found subjects with lower
endogenous nighttime melatonin peak levels had a stronger response to treatment with
exogenous melatonin.118 In our study, we did not see a vast difference in response to
supplementation in those with high versus low daytime melatonin levels. For example, a
participant with undetectable daytime melatonin levels had smaller changes in BTMs (ID
017, Appendix B) than a woman with higher daytime melatonin (ID 019, Appendix B).
Endogenous melatonin levels may indeed be a factor in how a person responds to
treatment; however, peak nighttime levels may be the best indicator of low versus high
melatonin secretors. Daytime levels may not be reflective of the peak night levels.
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Future studies should consider collecting an initial 24-hour salivary melatonin profile in
which participants collect saliva samples every 2-4 hours for one day. This information
may provide more details into the relationship between endogenous melatonin profiles
and responses to exogenous supplementation.
The pattern of change in BTM can depend on the mechanism of action of a
specific treatment. For example, antiresorptive therapies like bisphosphonates
significantly reduce bone resorption markers early in the treatment period while bone
formation markers do not decrease until approximately four weeks later.34 As
bisphosphonates act through inhibition of osteoclast action, the early response is a drop in
bone resorption markers. The bone formation markers do not decline until there is an
overall decrease in bone remodeling due to the decline in osteoclast activity. BTM
changes with anabolic therapy reflect a different pattern. After treatment with
teriparatide, bone formation markers significantly increase. Bone resorption markers do
not rise significantly above baseline until approximately six months after beginning
treatment.34 The main mechanism of action for each of these therapies determines
whether there will be an overall decrease (antiresorptive mechanism) or increase
(anabolic mechanism) in both osteoblast and osteoclast markers, reflecting the overall
effect of therapy on the bone remodeling process. Melatonin has several possible
mechanisms of action on bone including antiresorptive and anabolic actions (Figure 15).
As there is no currently available therapy with both antiresorptive and anabolic
mechanisms of action, the pattern of BTM changes with this type of treatment is not
established. One would speculate that there may be an initial drop in resorption makers
due to antiresorptive effects and a rise in formation markers due to anabolic effects,
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reflecting the unique mechanisms of action with melatonin. However, if the primary
mechanism of action is an anabolic effect through enhancement of osteoblast activity,
there may be an initial increase in bone formation markers followed by an increase in
resorption markers at later timepoints, indicating an overall increase in bone remodeling.
There are no published profiles of BTM changes with melatonin treatment in
perimenopausal women. Our study provides a framework illustrating how two markers
of bone remodeling, OC and NTX, respond to melatonin supplementation. A future study
should be conducted to investigate a panel of bone markers to determine the most
responsive markers to melatonin treatment.

Figure 15: Potential mechanisms of melatonin action on bone. Melatonin has several potential
mechanisms through which bone changes can occur including: (a) stimulation of osteoblast
differentiation through MT2 receptors46, 60; (b,c) increased secretion of OPG from osteoblasts
thereby reducing RANKL binding to RANK receptors63; and (d) neutralization of free radicals
produced by osteoclasts for bone resorption52. Figure Copyright © 2011 From Melatonin in the
Promotion of Health, 2nd edition by RR Watson. Reproduced by permission of Taylor and Francis
Group, LLC, a division of Informa plc.
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Currently, there are no standard guidelines regarding the use of bone turnover
markers in clinical practice or research. As such, there are no reference standards for
bone turnover marker values. Recently, the International Osteoporosis Foundation and
the International Federation of Clinical Chemistry and Laboratory Medicine (IOF/IFCC)
highlighted the need for reference standards with regards to which bone turnover markers
to measure in clinical studies in order to facilitate comparison of results between
studies.34 They have recommended the use of procollagen type I N propeptide (PINP) as
a marker of bone formation and carboxy-terminal cross-linking telopeptide of type I
collagen (CTX) as a marker of bone resorption based on criteria such as known
characteristics of each marker, availability of assay procedures, and requirements for
handling and stability. Perhaps consistency in the use of BTMs in clinical studies will
facilitate the development of clinical guidelines for collection, measurement, and
interpretation of marker changes with treatment.
It is difficult to determine if there is an established pattern of bone turnover
marker changes in perimenopausal women. Firstly, there are few prospective,
longitudinal studies examining how BTMs change over time in this population.
Additionally, the criteria used to classify a cohort as perimenopausal differs among
studies. Lastly, the specific biochemical markers studied and the methods of detection
vary widely. One prospective, longitudinal study by Hoshino et al.127 found an increase
in serum osteocalcin (bone formation), urinary deoxypyridinoline (DPD, bone
resorption), and urinary pyridinoline (PYD, bone resorption) in perimenopausal women;
however, measurements were only taken at baseline and after four years. The changes in
BTMs in the interim would have aided in establishing a possible pattern of BTM changes
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in perimenopausal women. Also, the perimenopausal group was defined in retrospect as
women who began the study in premenopause and completed the study in
postmenopause.127 The length of time each of the women was in the perimenopausal
stage could influence how BTMs changed within the four year study period. A second
longitudinal study of bone metabolism during the menopausal transition measured three
markers of bone resorption (PYD, DPD, and NTX in urine) and two markers of bone
formation [plasma OC and serum bone alkaline phosphatase (BAP)] four times in a one
year period.35 Seifert-Klauss et al.35 found significant increases in OC, PYD, and DPD
after twelve months in the perimenopausal group. NTX levels did not change over time
in this group but where significantly higher overall compared to premenopausal women.
The authors acknowledge their study may include some women who were 'late'
premenopausal at the beginning of the study in their perimenopausal cohort based on
their classification criteria.35 A similar longitudinal study published by Rosenbrock et al.
in 20029 attempted to illustrate the changes in BTMs over the course of two years.
Several markers of bone turnover were measured at 0, 3, 6, 12, and 24 months in
premenopausal, perimenopausal, and postmenopausal women. As with Seifert-Klauss et
al.35, this study may have included some women who were 'late' premenopausal at the
beginning of the study in their perimenopausal cohort. Over the course of the two-year
study, two out of five markers of bone resorption (PYD and DPD) increased over time in
the 19 perimenopausal women studied. Only one of the three bone formation markers
(OC) increased in perimenopausal women over the course of two years.9 This study is
perhaps the best illustration of how we would have expected the placebo group to
respond in our study. The placebo cohort showed no significant change in bone turnover
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over the six month study. Rosenbrock found significant changes over a two year time
period9 indicating the need for a longer study period in order to detect changes in
untreated women over time. We only followed the change in two bone turnover markers
for six months. It may take a longer treatment period to fully understand the impact of
melatonin on BTMs.
Markers of bone turnover can be utilized in clinical research to make inferences
about specific populations, but large biological variability has been an obstacle for
moving analysis of BTMs into clinical practice.128 The lack of significant differences
between the placebo and melatonin treatment groups may be a reflection of the variability
between individuals, which is more evident in a pilot study with small sample sizes.
Future studies investigating bone turnover marker changes in perimenopausal women
should focus on minimizing sources of variation. Controllable sources of variation in
BTM include diet and timing of sample collection.34, 129 In the current study, participants
were not required to fast. Depending on the markers investigated, fasting may be an
important factor. For instance, serum CTX levels are known to decrease by 20% after
breakfast.129 BTM levels can also vary depending on the timing of sample collection;
this is particularly true for bone resorption markers as the lowest values occur in the
afternoon and evening.129 In the current study, the majority of samples were taken in the
morning; however, some participants required afternoon appointments resulting in a later
blood collection time. Efforts should be made in future studies to standardize the blood
collection time, preferably in the morning. Menopausal status is also a source of variance
when measuring BTMs. Bone turnover markers are known to increase from
premenopause to postmenopause.34, 35, 129 Perimenopausal women present a unique
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challenge in that erratic endocrine changes characterize the perimenopausal state, which
could possibly influence bone marker expression.
Two cohort studies have compared BTMs between premenopausal and
perimenopausal women. A cross-sectional cohort study of women in Australia measured
several markers of bone resorption and bone formation in premenopausal,
perimenopausal, and postmenopausal women.8 Out of four bone resorption markers, only
one (urinary NTX) was significantly higher in perimenopausal women as compared to
premenopausal women. None of the three bone formation markers were different in
perimenopausal women as compared to those in premenopause. Interestingly, the authors
found a significant correlation with FSH levels and several, but not all, measured markers
of bone turnover such that high levels of FSH were correlated with increased BTMs.8 A
second cross-sectional study analyzed serum osteocalcin and urine NTX levels in preand early perimenopausal women from the SWAN study.14 No significant differences in
either bone marker between the two cohorts was found; however, in accordance with
Ebeling et al.8, a significant positive correlation was found between FSH and BTM
levels.14 FSH has been proposed to have a possible role in regulation of bone metabolism,
possibly through activation of FSH receptors on osteoclasts to stimulate bone
resorption.15 FSH levels increase as women transition through perimenopause into
menopause. Our sample population consisted of women in both early and late
perimenopause who most likely had a wide range of FSH values. The heterogeneity in
FSH levels may contribute to the variability in BTMs between individuals. The
variability in FSH levels may be reflective of the type of menstrual cycle occurring in
each woman. Anovulatory menstrual cycles, in which no mature oocyte is released,
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occur more often in perimenopause than premenopause.130-132 The lack of ovulation is
thought to result in sustained high levels of FSH.131, 132 Changes in bone marker
expression can differ between ovulatory and anovulatory cycles.10 Future studies would
benefit from measuring FSH levels to consider this factor into the analysis of BTMs
changes over time in perimenopausal women.
In addition to primary endpoints of bone health, we also measured secondary
endpoints focused on quality of life. The first aspect of quality of life we examined were
symptoms related to the menopausal transition. The MENQOL questionnaire was
utilized to detect changes in quality of life associated with vasomotor, psychosocial,
physical, and sexual menopausal symptoms. Daily journal entries were examined to chart
menstrual cycling. Melatonin has previously been examined for its use in the treatment of
vasomotor symptoms, but no significant effects were identified.133 Our study confirms
the lack of vasomotor effects as indicated by the lack of significant change in the
MENQOL vasomotor domain score (Table 4). Interestingly, we did detect a significant
improvement in subjective measures of physical menopausal symptoms with daily
nocturnal melatonin supplementation. Subjects taking melatonin also had fewer
menstrual periods during the six- month study (Figure 12). Taken together, these results
suggest a role for melatonin in improving patient quality of life during the menopausal
transition.
Due to fluctuating hormone levels, perimenopausal women experience irregular
and often heavy vaginal bleeding. Our study shows melatonin may influence the length of
time between menstrual cycles, possibly indicating a restoration of normal cycling
patterns. It has been hypothesized that melatonin may restore normal bleeding patterns in
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early postmenopausal women.83, 133 In a double-blind randomized controlled trial,
Secreto et al. found more postmenopausal women receiving melatonin treatment (3 mg
orally for three months) reported menstrual flow or spotting compared to women who did
not take melatonin.133 The authors speculate melatonin may resume menstrual flow in
early postmenopausal women; however, the inclusion criteria for the study included
women who had not had a menstrual period in the past six months. Some subjects may
technically have been in perimenopause until one year had passed without menstruation.
The inclusion of perimenopausal women could explain why some subjects experienced
bleeding or spotting. A study by Bellipanni et al. reported resumption of normal
menstrual cycles including bleeding and duration in 12 postmenopausal women taking 3
mg oral melatonin nightly.83 These women were all 1 to 2 years past their final menstrual
period. The restoration of normal bleeding patterns in these studies supports our findings
that melatonin treatment may regulate menstrual cycling in perimenopausal women.
Melatonin may play a role in the regulation of endocrine changes during perimenopause.
The hormonal imbalance in perimenopause is considered hyperestrogen relative
to hypoprogesterone.5 When compared to premenopausal women, perimenopausal
women have increased melatonin during the luteal phase, a time when progesterone is
also high.134 Likewise, melatonin levels increase with progestin levels in premenopausal
women taking a 3-phase contraceptive pill.134 While melatonin has a synergistic
relationship with progesterone,99, 134 it has an inverse relationship with estrogen such that
when estrogen levels are high melatonin levels are low.101-104

These relationships may

be explained, in part, by evidence implicating melatonin in the modulation of ovarian
function; however, the exact mechanisms are not well-understood. Melatonin
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concentrations in the ovary, specifically in preovulatory follicular fluid, are higher than in
serum samples indicating a role for melatonin in the ovary.90, 91 In addition, in vitro
experiments demonstrate the ability of melatonin to enhance progesterone secretion from
stimulated human granulosa cells94, 99 and corpus luteum.100 Melatonin receptor mRNA
transcripts93, 94 and binding sites95 have been discovered on human granulosa cells,
suggesting melatonin may influence ovarian function through receptor-mediated events.
A recent study investigated the impact of melatonin on serum progesterone levels in
women with low luteal phase serum progesterone.135 Administration of 3 mg oral
melatonin nightly during the luteal phase improved serum progesterone levels in 9 of 14
patients; whereas, only 2 of 11 placebo patients had improved progesterone levels.135
The interplay between melatonin and reproductive hormones points towards a possible
role for melatonin in stabilization of the hormonal imbalances that characterize
perimenopause. By balancing the fluctuations in hormone levels, melatonin may relieve
some of the more bothersome symptoms associated with perimenopause including
irregular bleeding patterns as evidenced by the fewer number of menstrual periods
experienced by women in the melatonin group (Figure 12). Improvement of physical
symptoms associated with perimenopause would enhance quality of life for women going
through the menopausal transition.
Analysis of baseline melatonin levels show more women in the melatonin group
(11/13) to have daytime serum melatonin levels below 40 pg/ml compared to placebo
(2/5). Women in perimenopause undergo periods of high estrogen secretion4, which
could possibly affect melatonin levels. This idea is supported by an inverse relationship
between estrogen and melatonin.102 Thus, the low melatonin levels in the melatonin-
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treated group could indicate higher estrogen levels, suggesting more women in the
melatonin group may have been in a hyperestrogen state. Future studies could also
measure estrogen to examine how melatonin levels may change with higher or lower
estrogen levels.
In addition to irregular bleeding patterns, perimenopause is often characterized by
sleep disturbances.6, 7 Melatonin is well-known for its ability to regulate sleep patterns47;
therefore, as part of our secondary endpoints, we examined the impact of melatonin on
sleep quality. Treatment with melatonin did not significantly change sleep quality as
measured by the PSQI survey. This survey is designed to identify “good” and “poor”
sleepers.116 On the 0-21 PSQI score scale, both groups of subjects had a mean starting
PSQI score around 5 (Table 3), indicating that the majority of the enrolled participants
may have already been experiencing “good” sleep. Therefore, small changes in sleep
quality, which may have been evident to the subjects, may not have been captured with
this specific sleep questionnaire. As sleep quality was a secondary endpoint of this study,
our measures relied on participant records to identify changes in sleeping patterns. We
found no change in the average number of hours slept per night with melatonin treatment
(Figure 6); however, participants also kept a normal daily routine throughout the study.
Thus, the number of hours of sleep may be more a product of normal scheduling rather
than a lack of effect by melatonin. A meta-analysis of studies examining the effects of
melatonin on sleep found a significant reduction in sleep onset latency, increased sleep
efficiency, and increased total duration of sleep with melatonin therapy as measured by
objective sleep endpoints. Interestingly, the authors discovered many studies that relied
on subjective measure of sleep found melatonin had no efficacy, indicating objective
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measures may be necessary to define small but significant changes in sleep quality.81
Nevertheless, the fact that the majority of melatonin subjects correctly identified their
treatment group based on reported improvements in sleep and well-being indicates
melatonin may alleviate the sleep disturbances experienced by perimenopausal women.
Melatonin may also improve blood pressure in perimenopausal women as
evidenced by the decreasing trend in both systolic and diastolic blood pressure over the
study period (Figure 14). The exact mechanisms of how melatonin modulates blood
pressure are not well-characterized but may involve antioxidant activity, activation of
MT2 receptors on the coronary artery and aorta, and regulation of central nervous system
areas involved in control of blood pressure.113 Nighttime melatonin administration has
been shown to significantly decrease nocturnal systolic and diastolic blood pressure in
healthy women.136 In this study, we selected women with blood pressure in the normal
range as a change in blood pressure was not our primary endpoint. Perimenopausal
women with rising blood pressure my further benefit from melatonin supplementation in
addition to its effect on physical symptoms of menopause.
This study was designed as a pilot study to examine the impact of melatonin
supplementation on bone health with secondary endpoints examining quality of life
issues in perimenopausal women. Limitations to this study include small sample sizes, a
significantly older population of women in the melatonin group, and heterogeneity in
terms of stage of perimenopause and prevalence of menopausal symptoms. Despite the
small sample sizes in this study, we detected a significant improvement in MENQOL
physical domain scores with nightly melatonin supplementation. Staging of menopause
can affect the perception of symptoms common in the menopausal transition. In this
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study, it is possible that women were in different stages of the perimenopausal transition
(early vs late).2 Those just beginning perimenopause may have different perceptions of
symptoms compared to women who have been in perimenopause for some time.
Additionally, women may have had variable responses to the effects of melatonin
depending on their hormone profile. As relief of menopausal symptoms was not the
primary outcome of this study, subjects were not stratified based on stage of menopause,
degree of menopausal symptoms, or hormonal profile. Thus, larger-scale studies with
group stratification may further substantiate the findings of this study related to the
effects of melatonin on quality of life issues in perimenopausal women. Additionally, we
utilized a dose of 3 mg of melatonin in this study. As there are currently no published
results regarding melatonin dosage and effects on bone, we chose a dose known to
produce a physiologic effect on circadian rhythm.110 A larger dose may produce a more
robust change in bone markers than was seen in this study. Future studies should
examine other dosages of melatonin to investigate how an increased dose may impact
changes in bone markers.
The main objective of this pilot study was to generate hypotheses and refine study
methods for future investigations. We were successful in recruiting perimenopausal
women to participate in this study. Retention of enrolled participants was high, most
likely because of monthly follow-up phone calls and a lack of adverse effects.
Recruitment strategies for future studies should focus on sources of publicity that allow
more details of the study to be given such as newspaper articles in local newspapers. We
did not find a significant change in biochemical markers of bone turnover with melatonin
treatment. We did, however, find a trend in the ratio of NTX to OC, possibly indicating a
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balancing of bone remodeling with treatment. In order to better detect changes in
markers of bone turnover, future studies should include measurement of several makers
of both resorption and formation. Serum samples should be taken in the early morning in
fasting participants to minimize sources of variability due to circadian patterns and diet.
Melatonin also improved quality of life scores related to physical symptoms of
menopause. Interestingly, we did not find an improvement of sleep patterns with
melatonin as measured by the PSQI survey. Serum FSH levels should be measured to
better classify participants as being in early or late perimenopause. The influence of
melatonin on menstrual cycling could be further explored through more detailed
questions in the daily journal entries. Information about the extent of menstrual bleeding,
symptoms associated with menstruation like breast tenderness, and duration of the
menstrual period would allow for more exploration into how melatonin influences
menstrual cycling. The use of activity watches (wrist actigraphy) in conjunction with
sleep diaries may provide a more detailed account of sleep disturbances experienced by
study participants allowing for more objective analysis of the ability of melatonin to
improve sleep quality in perimenopausal women. Overall, our study illustrates the
potential for melatonin to enhance quality of life in perimenopausal women by reducing
physical symptoms associated with the menopausal transition. Melatonin may also
protect women from bone loss by maintaining balance between osteoblast and osteoclast
activity. A more extensive, longitudinal study into the long-term effects of melatonin
supplementation throughout the perimenopausal transition into menopause is warranted.
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Monthly T-Scores – Melatonin Group
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Monthly T-Scores – Melatonin Group (continued)
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Bone Turnover Markers – Placebo Group
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Bone Turnover Markers – Melatonin Treatment Group (continued)
 NTX (nM BCE)
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Melatonin Serum Levels at Baseline and Month 6
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Blood Pressure Measurements – Placebo Group
 Systolic Pressure
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Blood Pressure Measurements – Melatonin Treatment Group
 Systolic Pressure
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Blood Pressure Measurements – Melatonin Treatment Group (continued)

 Systolic Pressure
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